基因6型慢性丙型肝炎的流行病学特征及抗病毒疗效分析

黄锦妮; 江建宁; 梁丹丹; 龙诗雨; 董国珍; 苏曼; 李继娇; 滕春玲; 张萍; 苏明华

doi:10.3969/j.issn.1001-5256.2022.04.011

基因6型慢性丙型肝炎的流行病学特征及抗病毒疗效分析

DOI: 10.3969/j.issn.1001-5256.2022.04.011

广西医科大学第一附属医院感染性疾病科，南宁 530021

基金项目:

广西医疗卫生适宜技术开发与推广应用项目 (S2019108);

南宁市青秀区科学研究与技术开发计划 (2013ZH02);

广西壮族自治区教育厅高校科研项目 (YB2014064)

伦理学声明：本研究方案于2020年12月29日经由广西医科大学第一附属医院伦理委员会审批，批号：伦审2020(KY-E-187)号，患者均签署知情同意书。

利益冲突声明：本研究不存在研究者、伦理委员会成员、受试者监护人以及与公开研究成果有关的利益冲突。

作者贡献声明：黄锦妮对研究数据进行了获取分析及解释过程，并修改文章关键内容；江建宁、苏明华负责研究的思路或设计，参与修改文章关键内容；梁丹丹、龙诗雨、董国珍、苏曼、李继娇、滕春玲、张萍参与研究数据的获取分析过程。

详细信息

通信作者:
苏明华，smh9292@163.com

计量
- 文章访问数: 362
- HTML全文浏览量: 100
- PDF下载量: 40
- 被引次数: 0
出版历程
- 收稿日期: 2021-08-11
- 录用日期: 2021-09-14
- 出版日期: 2022-04-20

Epidemiological features and antiviral response of genotype 6 chronic hepatitis C

Department of Infection Diseases, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China

Research funding:

Guangxi Medical and Health Appropriate Technology Development and Application Project (S2019108);

Qingxiu District Scientific Research and Technology Development Project of Nanning City (2013ZH02);

Guangxi Zhuang Autonomous Region Education Department University Scientific Research Project (YB2014064)

More Information

Corresponding author: SU Minghua, smh9292@163.com(ORCID: 0000-0001-7831-6580)

摘要

摘要: 目的分析广西地区基因6型慢性丙型肝炎(CHC)患者流行病学特点和抗病毒疗效。方法选取2012年12月—2020年12月在广西医科大学第一附属医院收治的97例基因6型CHC患者，其中62例经抗病毒治疗。62例患者分为干扰素治疗组(n=22)和直接抗病毒药物(DAA)治疗组(n=40)。收集患者的一般人口学资料及HCV RNA、肝功能、血常规、肾功能等指标。计数资料组间比较采用χ²检验。结果 97例患者中男69例(71.1%)，女28例(28.9%)，平均年龄(41.97±10.12)岁，30~40岁感染者居多，占47.4%(46/97)。基因6a型95例(97.9%)，基因6e、6xa型各1例。静脉吸毒占明确感染途径患者的63.1%(41/65)，医疗相关操作14例、输血相关9例及性接触4例。干扰素治疗组总体第4周获快速病毒学应答(RVR)率、停药时病毒检测不到(Epoint)率、停药后12周获持续病毒学应答(SVR12)率、停药后24周获持续病毒学应答(SVR24)率分别为81.8%(18/22)、86.4%(19/22)、81.8%、81.8%，其中1例出现复发。DAA治疗组40例均为初治患者(非肝硬化33例，代偿期肝硬化7例)，总体RVR、Epoint、SVR12率分别为87.5%(35/40)、100%、100%，无治疗失败或复发者。各DAA方案虽RVR率不同，但SVR12率均为100%。代偿期肝硬化及合并其他疾病的患者SVR12率均达100%。结论广西地区基因6型CHC患者的感染途径主要以静脉药瘾为主，男性多见，亚型主要为6a型；DAA治疗相对于干扰素治疗有更高的病毒学应答率，SVR12率为100%；代偿期肝硬化与非肝硬化患者的SVR12率无差别。
- 丙型肝炎 /
- 流行病学 /
- 治疗学
Abstract: Objective To investigate the epidemiological features and antiviral response of patients with genotype 6 chronic hepatitis C (CHC) in Guangxi, China. Methods A total of 97 patients with genotype 6 CHC who were admitted to The First Affiliated Hospital of Guangxi Medical University from December 2012 to December 2020 were enrolled, among whom 62 patients were given antiviral therapy. The 62 patients receiving antiviral therapy were divided into interferon group with 22 patients and direct-acting antiviral agent (DAA) group with 40 patients. Related data were collected, including general demographic data, HCV RNA, liver function, routine blood test results, and renal function. The chi-square test was used for comparison of categorical data between groups. Results Among the 97 patients, there were 69 male patients (71.1%) and 28 female patients (28.9%), with a mean age of 41.97±10.12 years, and the patients aged 30-40 years accounted for 47.4% (46/97). Of all 97 patients, 95 (97.9%) had genotype 6a, 1 had genotype 6e, and 1 had genotype 6xa. Among the 65 patients with a definite route of infection, 41 (63.1%) had intravenous drug use, 14 had medical-related operations, 9 had blood transfusion, and 4 had sexual contact as the route of infection. For the interferon group, the rapid virologic response (RVR) rate at week 4 was 81.8% (18/22), the rate of undetectable virus at the time of drug withdrawal (Epoint) was 86.4% (19/22), the rate of sustained virologic response at 12 weeks after drug withdrawal (SVR12) was 81.8%, and the rate of sustained virological response at 24 weeks after drug withdrawal (SVR24) was 81.8%; 1 patient in this group experienced recurrence. All 40 patients in the DAA group were previously untreated patients (33 patients without liver cirrhosis and 7 patients with compensated liver cirrhosis), with an overall RVR rate of 87.5%(35/40), an Epoint rate of 100%, and an SVR12 rate of 100%, and there was no treatment failure or recurrence. Although different DAA regimens had different RVR rates, they all had a SVR12 rate of 100%. The patients with compensated liver cirrhosis and other diseases had a SVR12 rate of 100%. Conclusion Intravenous drug addiction is the main route of infection for patients with genotype 6 CHC in Guangxi, and CHC is more common in men, with genotype 6a as the main subtype. DAA treatment has a higher virologic response rate than interferon treatment, with an SVR12 rate of 100%. There is no significant difference in SVR12 rate between the patients with compensated liver cirrhosis and those without liver cirrhosis.
- Hepatitis C /
- Epidemiology /
- Therapeutics

HTML全文

图 1 不同治疗方案的病毒学应答率

Figure 1. Virological response of different treatment regimens

下载: 全尺寸图片幻灯片

表 1 不同治疗方案及疗程

Table 1. Different treatment plans and courses of treatment

治疗方案	例数	疗程(周)
PR方案	18	24~48
PR+SOF	4	24~48
SOF+VEL	17	12
SOF+LDV	7	12
SOF+DCV	11	12
SOF+RBV	5	24

下载: 导出CSV

表 2 97例患者流行病学特征及基线资料

Table 2. Epidemiological characteristics and baseline data of 97 patients

项目	数值
性别[例(%)]
男性	69(71.1)
女性	28(28.9)
年龄(岁)	41.97±10.12
基因型[例(%)]
6a型	95(98)
6xa型	1(1)
6e型	1(1)
传播途径明确(例)	65¹⁾
静脉吸毒	41
医疗相关操作	14
输血相关	9
性接触	4
接受干扰素治疗(例)	22
接受DAA治疗(例)	40²⁾
HCV RNA(IU/mL)	122.0(8.3~320.0)×10⁵
ALT(U/L)	157(78~211)
AST(U/L)	105(66~199)
注：1)3例有双重传播途径，其中合并静脉吸毒+医疗相关操作1例，静脉吸毒+输血相关1例，医疗相关操作+性接触1例；2)接受DAA治疗的40例患者中代偿期肝硬化7例，非肝硬化33例，均为初治患者。

下载: 导出CSV

参考文献(24)

[1]	LAVANCHY D. The global burden of hepatitis C[J]. Liver Int, 2009, 29(Suppl 1): 74-81. DOI: 10.1111/j.1478-3231.2008.01934.x.
[2]	MOHD HANAFIAH K, GROEGER J, FLAXMAN AD, et al. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence[J]. Hepatology, 2013, 57(4): 1333-1342. DOI: 10.1002/hep.26141.
[3]	CHEN YS, LI L, CUI FQ, et al. A sero-epidemiological study on hepatitis C in China[J]. Chin J Epidemiol, 2011, 3(9): 888-891. DOI: 10.3760/cma.j.issn.0254-6450.2011.09.009. 陈园生, 李黎, 崔富强, 等. 中国丙型肝炎血清流行病学研究[J]. 中华流行病学杂志, 2011, 3(9): 888-891. DOI: 10.3760/cma.j.issn.0254-6450.2011.09.009.
[4]	FATTOVICH G, STROFFOLINI T, ZAGNI I, et al. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors[J]. Gastroenterology, 2004, 127(5 Suppl 1): S35-S50. DOI: 10.1053/j.gastro.2004.09.014.
[5]	The field of anti-HCV therapy is progressing rapidly, and hepatitis C can be cured[J]. Chin Community Doct, 2018, 34(28): 172. 抗HCV治疗领域进展迅速, 丙肝已经可以治愈[J]. 中国社区医师, 2018, 34(28): 172.
[6]	LEE MH, HSIAO TI, SUBRAMANIAM SR, et al. HCV genotype 6 increased the risk for hepatocellular carcinoma among asian patients with liver cirrhosis[J]. Am J Gastroenterol, 2017, 112(7): 1111-1119. DOI: 10.1038/ajg.2017.123.
[7]	FEENEY ER, CHUNG RT. Antiviral treatment of hepatitis C[J]. BMJ, 2014, 348: g3308. DOI: 10.1136/bmj.g3308.
[8]	Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association. Guidelines for the prevention and treatment of hepatitis C (2019 version)[J]. J Clin Hepatol, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008. 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2670-2686. DOI: 10.3969/j.issn.1001-5256.2019.12.008.
[9]	LI C, PHAM VH, ABE K, et al. Nine additional complete genome sequences of HCV genotype 6 from Vietnam including new subtypes 6xb and 6xc[J]. Virology, 2014, 468-470: 172-177. DOI: 10.1016/j.virol.2014.08.006.
[10]	THONG VD, AKKARATHAMRONGSIN S, POOVORAWAN K, et al. Hepatitis C virus genotype 6: Virology, epidemiology, genetic variation and clinical implication[J]. World J Gastroenterol, 2014, 20(11): 2927-2940. DOI: 10.3748/wjg.v20.i11.2927.
[11]	TSUKIYAMA-KOHARA K, KOHARA M. Hepatitis C virus: Viral quasispecies and genotypes[J]. Int J Mol Sci, 2017, 19(1): 23. DOI: 10.3390/ijms19010023.
[12]	LI C, BARNES E, NEWTON PN, et al. An expanded taxonomy of hepatitis C virus genotype 6: Characterization of 22 new full-length viral genomes[J]. Virology, 2015, 476: 355-363. DOI: 10.1016/j.virol.2014.12.025.
[13]	METTIKANONT P, BUNCHORNTAVAKUL C, REDDY KR. Systematic review: Epidemiology and response to direct-acting antiviral therapy in genotype 6 chronic hepatitis C virus infection[J]. Aliment Pharmacol Ther, 2019, 49(5): 492-505. DOI: 10.1111/apt.15100.
[14]	CHEN Y, YU C, YIN X, et al. Hepatitis C virus genotypes and subtypes circulating in Mainland China[J]. Emerg Microbes Infect, 2017, 6(11): e95. DOI: 10.1038/emi.2017.77.
[15]	MOHD SUAN MA, SAID SM, LIM PY, et al. Risk factors for hepatitis C infection among adult patients in Kedah state, Malaysia: A case-control study[J]. PLoS One, 2019, 14(10): e0224459. DOI: 10.1371/journal.pone.0224459.
[16]	MAO Q. Changes in the distribution pattern of HCV genotypes in China and the RGT strategy of HCV-6[C]//The 4th National Academic Conference on Progress in Basic and Clinical Research on Chronic and Severe Viral Hepatitis. 2014: 111-112. 毛青. 中国HCV基因型分布模式变迁及HCV-6型的RGT策略[C]//第四届全国病毒性肝炎慢性化、重症化基础与临床研究进展学术会议论文汇编. 2014: 111-112.
[17]	TANG W, SU MH, JIANG JN, et al. Epidemiological characteristics and genotype distribution of hepatitis C virus in Guangxi[J]. World Chin J Dig, 2014, 22(9): 1300-1306. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201409022.htm 唐维, 苏明华, 江建宁, 等. 广西地区丙型肝炎病毒的基因型分布与流行病学特征[J]. 世界华人消化杂志, 2014, 22(9): 1300-1306. https://www.cnki.com.cn/Article/CJFDTOTAL-XXHB201409022.htm
[18]	WEI Z, SU MH, JIANG JN, et al. Epidemiological characteristics and therapeutic strategies of hepatitis C virus genotype 6 in Guangxi area[J]. Chin J Infect Dis, 2015, 33(7): 409-414. DOI: 10.3760/cma.j.issn.1000-6680.2015.07.008. 韦智, 苏明华, 江建宁, 等. 广西地区丙型肝炎病毒基因6型的流行特征及治疗分析[J]. 中华传染病杂志, 2015, 33(7): 409-414. DOI: 10.3760/cma.j.issn.1000-6680.2015.07.008.
[19]	BENÍTEZ-GUTIÉRREZ L, BARREIRO P, LABARGA P, et al. Prevention and management of treatment failure to new oral hepatitis C drugs[J]. Expert Opin Pharmacother, 2016, 17(9): 1215-1223. DOI: 10.1080/14656566.2016.1182156.
[20]	HLAING N, MITRANI RA, AUNG ST, et al. Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotypes 1-4 and 6 in Myanmar: Real-world experience[J]. J Viral Hepat, 2017, 24(11): 927-935. DOI: 10.1111/jvh.12721.
[21]	MOTAWI T, SHAKER OG, HUSSEIN RM, et al. Polymorphisms of α1- antitrypsin and Interleukin-6 genes and the progression of hepatic cirrhosis in patients with a hepatitis C virus infection[J]. Balkan J Med Genet, 2016, 19(2): 35-44. DOI: 10.1515/bjmg-2016-0034.
[22]	YANG G, SU MH, JIANG JN, et al. Resistance-associated variants in the non-structural protein 5B region in patients with hepatitis C virus genotype 1b infection in Guangxi, China[J]. J Clin Hepatol, 2019, 35(5): 992-995. DOI: 10.3969/j.issn.1001-5256.2019.05.012. 阳光, 苏明华, 江建宁, 等. 广西地区HCV 1b型感染者NS5B区基因耐药多态性分析[J]. 临床肝胆病杂志, 2019, 35(5): 992-995. DOI: 10.3969/j.issn.1001-5256.2019.05.012.
[23]	ASSELAH T, LEE SS, YAO BB, et al. Efficacy and safety of glecaprevir/pibrentasvir in patients with chronic hepatitis C virus genotype 5 or 6 infection (ENDURANCE-5, 6): An open-label, multicentre, phase 3b trial[J]. Lancet Gastroenterol Hepatol, 2019, 4(1): 45-51. DOI: 10.1016/S2468-1253(18)30341-8.
[24]	KU KS, CHODAVARAPU RK, MARTIN R, et al. Sequencing analysis of NS3/4A, NS5A, and NS5B genes from patients infected with hepatitis C virus genotypes 5 and 6[J]. J Clin Microbiol, 2016, 54(7): 1835-1841. DOI: 10.1128/JCM.00238-16.